258 related articles for article (PubMed ID: 16973883)
1. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
Woo S; Krzyzanski W; Jusko WJ
J Pharmacol Exp Ther; 2006 Dec; 319(3):1297-306. PubMed ID: 16973883
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.
Ramakrishnan R; Cheung WK; Wacholtz MC; Minton N; Jusko WJ
J Clin Pharmacol; 2004 Sep; 44(9):991-1002. PubMed ID: 15317827
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys.
Ramakrishnan R; Cheung WK; Farrell F; Joffee L; Jusko WJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):324-31. PubMed ID: 12676891
[TBL] [Abstract][Full Text] [Related]
4. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin.
Woo S; Jusko WJ
Drug Metab Dispos; 2007 Sep; 35(9):1672-8. PubMed ID: 17576810
[TBL] [Abstract][Full Text] [Related]
5. Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
Biopharm Drug Dispos; 2010 Jul; 31(5-6):298-315. PubMed ID: 20578212
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers.
Woo S; Krzyzanski W; Duliege AM; Stead RB; Jusko WJ
J Clin Pharmacol; 2008 Jan; 48(1):43-52. PubMed ID: 18025524
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
J Pharmacol Exp Ther; 2010 Sep; 334(3):897-910. PubMed ID: 20501635
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.
Krzyzanski W; Jusko WJ; Wacholtz MC; Minton N; Cheung WK
Eur J Pharm Sci; 2005 Nov; 26(3-4):295-306. PubMed ID: 16102948
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.
Chanu P; Gieschke R; Charoin JE; Pannier A; Reigner B
J Clin Pharmacol; 2010 May; 50(5):507-20. PubMed ID: 20179322
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats.
Yoon WH; Park SJ; Kim IC; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):227-40. PubMed ID: 9226757
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes.
Varlet-Marie E; Gaudard A; Audran M; Gomeni R; Bressolle F
Int J Sports Med; 2003 May; 24(4):252-7. PubMed ID: 12784166
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats.
Wiczling P; Ait-Oudhia S; Krzyzanski W
Cytometry A; 2009 Jul; 75(7):584-92. PubMed ID: 19437531
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusion.
Sans T; Joven J; Vilella E; Masdeu G; Farrè M
Clin Exp Pharmacol Physiol; 2000 Mar; 27(3):179-84. PubMed ID: 10744344
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of lyophilized recombinant human erythropoietin-alpha following single-dose subcutaneous administration in premature newborns.
Melo AM; Costa MT; Porta V; Vaz FA
J Matern Fetal Neonatal Med; 2005 Jan; 17(1):55-8. PubMed ID: 15804788
[TBL] [Abstract][Full Text] [Related]
17. The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats.
Wiczling P; Krzyzanski W; Zychlińska N; Lewandowski K; Kaliszan R
Biopharm Drug Dispos; 2014 Sep; 35(6):330-40. PubMed ID: 24888906
[TBL] [Abstract][Full Text] [Related]
18. The erythropoietic effects of interleukin 6 and erythropoietin in vivo.
Ulich TR; del Castillo J; Yin SM; Egrie JC
Exp Hematol; 1991 Jan; 19(1):29-34. PubMed ID: 1989892
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients.
Fujisaka Y; Tamura T; Ohe Y; Kunitoh H; Sekine I; Yamamoto N; Nokihara H; Horiike A; Kodama T; Saijo N
Jpn J Clin Oncol; 2006 Aug; 36(8):477-82. PubMed ID: 16901911
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic studies following percutaneous absorption of erythropoietin micropiles to rats.
Ito Y; Shiroyama K; Yoshimitsu J; Ohashi Y; Sugioka N; Takada K
J Control Release; 2007 Aug; 121(3):176-80. PubMed ID: 17628163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
